Pharmacogenetics of anti-HIV drugs

被引：54

作者：

Telenti, A. ^{[1
]}

Zanger, U. M. ^{[2
,3
]}

机构：

[1] Univ Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland

[2] Univ Tubingen, D-72074 Tubingen, Germany

[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2008年 / 48卷

关键词：

protease inhibitors; non-nucleoside reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; HIV susceptibility; ADME proteins;

D O I：

10.1146/annurev.pharmtox.48.113006.094753

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.

引用

页码：227 / 256

页数：30

共 161 条

[61]

HUGHES S, 2007, IN PRESS PHARM STAT

[62] Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study [J].

Hulgan, T ;

Haas, DW ;

Haines, JL ;

Ritchie, MD ;

Robbins, GK ;

Shafer, RW ;

Clifford, D ;

Kallianpur, AR ;

Summar, M ;

Canter, JA .

AIDS, 2005, 19 (13) :1341-1349

[63]

Hustert E, 2001, DRUG METAB DISPOS, V29, P1454

[64] CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir [J].

Josephson, F. ;

Allqvist, A. ;

Janabi, M. ;

Sayi, J. ;

Aklillu, E. ;

Jande, M. ;

Mahindi, M. ;

Burhenne, J. ;

Bottiger, Y. ;

Gustafsson, L. L. ;

Haefeli, W. E. ;

Bertilsson, L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :708-712

[65] Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells [J].

Kameyama, Y ;

Yamashita, K ;

Kobayashi, K ;

Hosokawa, M ;

Chiba, K .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (07) :513-522

[66] A "silent" polymorphism in the MDR1 gene changes substrate specificity [J].

Kimchi-Sarfaty, Chava ;

Oh, Jung Mi ;

Kim, In-Wha ;

Sauna, Zuben E. ;

Calcagno, Anna Maria ;

Ambudkar, Suresh V. ;

Gottesman, Michael M. .

SCIENCE, 2007, 315 (5811) :525-528

[67] Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 [J].

Kirchheiner, J ;

Klein, C ;

Meineke, I ;

Sasse, J ;

Zanger, UM ;

Mürdter, TE ;

Roots, I ;

Brockmöller, J .

PHARMACOGENETICS, 2003, 13 (10) :619-626

[68] Genetic variability of CYP2B6 in populations of African and Asian origin:: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz [J].

Klein, K ;

Lang, T ;

Saussele, T ;

Barbosa-Sicard, E ;

Schunck, WH ;

Eichelbaum, M ;

Schwab, M ;

Zanger, UM .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (12) :861-873

[69]

KLIMECKI WT, 1994, BLOOD, V83, P2451

[70] SNPs, silent but not invisible [J].

Komar, Anton A. .

SCIENCE, 2007, 315 (5811) :466-467

← 2 3 4 5 6 7 8 9 10 11 →